Loading...
•
Sep 30, 2024
GoodRx Q3 2024 Earnings Report
GoodRx experienced revenue growth and improved profitability, driven by pharma manufacturer solutions and prescription transactions.
Key Takeaways
GoodRx reported an 8% increase in revenue to $195.3 million and a net income of $4.0 million for Q3 2024, compared to a net loss of $38.5 million in the same period last year. The growth was primarily driven by a 77% increase in pharma manufacturer solutions revenue and a 4% increase in prescription transactions revenue.
Revenue and Adjusted Revenue reached $195.3 million.
Net income was $4.0 million, with a net income margin of 2.0%.
Adjusted EBITDA was $65.0 million, resulting in an Adjusted EBITDA Margin of 33.3%.
The company exited the quarter with over 7 million consumers of prescription-related offerings.
GoodRx
GoodRx
GoodRx Revenue by Segment
Revenue by Segment
Prescription Transactions Revenue
CapyFin.comSubscription Revenue
CapyFin.comPharma Manufacturer Solutions Revenue
CapyFin.com Forward Guidance
For the fourth quarter of 2024, GoodRx anticipates revenue and Adjusted Revenue of approximately $200 million and Adjusted EBITDA Margin of about 34%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income